Palvella Therapeutics, Inc. (NASDAQ:PVLA – Get Free Report) COO Kathleen Goin sold 4,302 shares of the stock in a transaction dated Wednesday, March 18th. The stock was sold at an average price of $117.99, for a total transaction of $507,592.98. The sale was disclosed in a legal filing with the SEC, which can be accessed […]

CytomX Therapeutics, Inc. (NASDAQ:CTMX – Get Free Report) CEO Sean Mccarthy sold 118,969 shares of the company’s stock in a transaction that occurred on Tuesday, March 17th. The shares were sold at an average price of $6.42, for a total value of $763,780.98. Following the sale, the chief executive officer directly owned 1,078,922 shares of […]

CytomX Therapeutics, Inc. (NASDAQ:CTMX – Get Free Report) insider Yu-Waye Chu sold 21,279 shares of the business’s stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $6.42, for a total transaction of $136,611.18. Following the completion of the sale, the insider owned 189,446 shares in the company, […]

Allogene Therapeutics, Inc. (NASDAQ:ALLO – Get Free Report) SVP Benjamin Machinas Beneski sold 4,835 shares of the business’s stock in a transaction on Monday, March 16th. The shares were sold at an average price of $2.47, for a total transaction of $11,942.45. Following the sale, the senior vice president owned 198,205 shares of the company’s […]

Century Therapeutics, Inc. (NASDAQ:IPSC – Get Free Report) insider Gregory Russotti sold 10,076 shares of Century Therapeutics stock in a transaction on Thursday, March 12th. The stock was sold at an average price of $2.55, for a total transaction of $25,693.80. Following the completion of the transaction, the insider directly owned 515,427 shares of the […]

Entrada Therapeutics, Inc. (NASDAQ:TRDA – Get Free Report) COO Nathan Dowden sold 11,894 shares of the business’s stock in a transaction on Tuesday, March 10th. The stock was sold at an average price of $13.05, for a total transaction of $155,216.70. Following the transaction, the chief operating officer owned 198,588 shares in the company, valued […]

Enliven Therapeutics, Inc. (NASDAQ:ELVN – Get Free Report) CFO Benjamin Hohl sold 10,000 shares of the stock in a transaction on Friday, March 6th. The shares were sold at an average price of $29.58, for a total value of $295,800.00. Following the completion of the sale, the chief financial officer owned 51,000 shares in the […]